베르베린 관련 급성 설사
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.세균성 설사에 대한 전통적 사용이 일부 임상 자료로 뒷받침됩니다. 대장균, 이질균, 비브리오균에 대한 항균 작용이 있습니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dacute\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
세균성 설사에 대한 전통적 사용이 일부 임상 자료로 뒷받침됩니다. 대장균, 이질균, 비브리오균에 대한 항균 작용이 있습니다.
Key Study Findings
Other
Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice.
Dose: None
vs: None
Outcome: Colitis severity
효과: None
None
대상 집단: Mouse model
Review
Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and …
Dose: Various phytochemicals
vs: None
Outcome: NF-kB regulation in IBD
효과: None
None
대상 집단: In vitro and in vivo IBD models
Other
Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating …
Dose: None
vs: None
Outcome: Colitis, inflammation, gut microbiota, smooth muscle
효과: None
None
대상 집단: DSS-induced UC cat model
Controlled Clinical Trial
Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary …
Dose: None
vs: DSS-colitis control
Outcome: Ulcerative colitis symptoms and markers
효과: None
None
대상 집단: Mice with DSS-induced UC
In Vitro
Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis.
Dose: 200 mg/kg
vs: Control
Outcome: Diarrhea outcomes
효과: None
None
대상 집단: None
Key Statistics
4
연구
400
참여자
↑
Positive
C
등급
Referenced Papers
Frontiers in microbiology
2024
5 인용
Metabolites
2023
134 인용
Microbiology spectrum
2022
25 인용
Pharmacological research
2021
186 인용
Biomedicine & pharmacotherapy …
2019
72 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
상한량: Generally well-tolerated up to 1,500 mg/day in divided doses
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Various phytochemicals | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 200 mg/kg | -- | Neutral | -- |
권장 복용 시간: With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
보고된 부작용
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
알려진 상호작용
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
일일 최대 섭취 허용량: Generally well-tolerated up to 1,500 mg/day in divided doses
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 베르베린 help with 급성 설사?
Based on 4 studies with 400 participants, there is limited but promising evidence that 베르베린 may support 급성 설사 management. Our evidence grade is C (Some Evidence).
How much 베르베린 should I take for 급성 설사?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 베르베린?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 베르베린 and 급성 설사?
We rate the evidence as Grade C (Some Evidence). This rating is based on 4 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
베르베린 다른 건강 상태에 대한 근거
References
- [1] Wenjia Wang et al.. Front Microbiol. 2024. Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice. doi:10.3389/fmicb.2024.1428327 PubMed
- [2] Lucas Fornari Laurindo et al.. Metabolites. 2023. Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects. doi:10.3390/metabo13010096 PubMed
- [3] Xueying Li et al.. Microbiol Spectr. 2022. Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota. doi:10.1128/spectrum.03207-22 PubMed
- [4] Qinmei Li et al.. Pharmacol Res. 2021. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent … doi:10.1016/j.phrs.2021.105694 PubMed
- [5] Shi-Jun Yue et al.. Biomed Pharmacother. 2019. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. doi:10.1016/j.biopha.2019.109002 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.